Integrative Chiropractic and Hormone Physiology Benefits

Integrative Chiropractic Care, Hormone Physiology, PCOS, PSA Decision-Making, and DHEA: An Evidence-Guided Clinical Journey

Abstract

In this educational post, I walk you through an integrated, first-person exploration of hormone transport and signaling, the role of sex hormone-binding globulin (SHBG) in metabolic health, contemporary polycystic ovary syndrome (PCOS) assessment and treatment, prostate-specific antigen (PSA) clinical decision-making using percent free PSA and velocity, and the clinical utility of dehydroepiandrosterone (DHEA). I weave in my clinical observations as an integrative chiropractor and family nurse practitioner, and show where integrative chiropractic care fits: neuro-musculoskeletal alignment, autonomic balance, and targeted lifestyle interventions that modulate insulin resistance, gut dysbiosis, and neuroendocrine axes. You will see how modern diagnostics, evidence-based protocols, and patient-centered strategies interact to improve outcomes for all individuals across endocrine and metabolic conditions.

Section 1: Understanding SHBG and Why More Is Often Better

As Dr. Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I start with a critical transport protein: sex hormone-binding globulin (SHBG). Clinically, many wonder: “How do I lower SHBG to increase free testosterone?” The surprising answer, supported by modern literature, is that lower SHBG generally correlates with worse metabolic status. SHBG is synthesized in the liver and binds androgens (with higher affinity for testosterone than estradiol), buffering hormonal flux and delivering hormone to tissues. When a hormone is bound to SHBG, the circulating free fraction decreases, but tissue delivery remains regulated. Upon receptor binding and cellular uptake, hormones exert their genomic and non-genomic effects.

• Key concept: Low SHBG is an early marker of insulin resistance, metabolic syndrome, and higher cardiovascular risk (Plymate et al., 2022; Ding et al., 2009).
• Clinical takeaway: We should not reflexively lower SHBG. Instead, correct the drivers—insulin resistance, visceral adiposity, and hepatic inflammation—and optimize total testosterone to appropriately saturate receptors.

Physiological underpinning

Insulin and hepatic lipogenesis downregulate SHBG production, while estrogens and lower insulin favor higher SHBG. Thus, hyperinsulinemia correlates with low SHBG, increased free androgens, and downstream dermatologic or reproductive symptoms. SHBG tracks earlier than A1C in some patients, flagging metabolic stress before glycemic indices fully drift.

Why receptor saturation strategy matters

In patients with high SHBG and symptoms of androgen deficiency, increasing total testosterone can saturate tissue receptors sufficiently that a clinically meaningful level of free testosterone remains. This explains why carefully titrated androgen therapy—or natural supports such as mineral-rich adaptogens like shilajit—may help certain patients feel better by improving bioavailable androgen despite high SHBG. The clinical rationale is to achieve adequate target tissue occupancy without chasing lower SHBG levels, which may increase metabolic risk.

Evidence signals

• Low SHBG predicts insulin resistance and metabolic dysfunction across cohorts (Ding et al., 2009).
• SHBG interacts with cardiometabolic risk; improving insulin sensitivity often raises SHBG and improves risk profiles (Plymate et al., 2022).

Section 2: PCOS Reframed: Gut, Insulin Resistance, and Phenotypic Diversity

PCOS is among the most common endocrine disorders in women, yet often missed because it is phenotypically diverse. The classic triad—obesity, acne, hirsutism—is not universal. Many patients present with irregular, painful cycles or fertility challenges without overt hyperandrogenic signs. An elevated LH: FSH ratio (>2:1 in some cases), high free testosterone, and DHEA-S can support the diagnosis, alongside Rotterdam criteria (two of three: oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) (Teede et al., 2018).

• Phenotypes:
  • Hyperandrogenic with hirsutism and cystic acne.
  • Non-higher weight with irregular cycles and fertility issues.
  • Insulin-resistant phenotype with low SHBG and high free testosterone.
• Drivers:
  • Hyperinsulinemia lowers SHBG, raises ovarian androgen production, and sensitizes androgen receptors.
  • Gut dysbiosis and intestinal permeability contribute to systemic inflammation, insulin resistance, and disruption of the HPO axis (Borgo et al., 2023).

My clinical observations

At my practices, I routinely see athletes and lean women with severe menstrual pain, irregular cycles, normal total testosterone but high free testosterone, and elevated LH: FSH ratios. A recent patient—tall, fit, in her early 20s—presented with debilitating cramps and irregular cycles. Labs showed high free T, elevated LH-to-FSH ratio, and high DHEA-S, without hirsutism or acne. We focused on gut evaluation with stool testing, addressed insulin resistance, and implemented a comprehensive lifestyle plan rather than reflexively prescribing only receptor blockers.

Physiology-driven treatment rationale

• Insulin-lowering tends to increase SHBG, reducing free androgen burden and symptom expression.
• GLP-1 receptor agonists and metformin improve insulin signaling, reduce hepatic steatosis, and raise SHBG (Davies et al., 2015; UKPDS Group, 1998).
• Spironolactone, as an androgen receptor antagonist, helps hirsutism/acne while the root causes are being corrected; typical dosing for hirsutism is 100 mg/day, with symptom improvement over 6–12 months (Martin et al., 2021).
• Lifestyle: anti-inflammatory dietary patterns, intermittent fasting, and resistance training improve insulin sensitivity, adipokine balance, and SHBG levels.

Integrative chiropractic care fits

In PCOS patients, I use integrative chiropractic care to modulate autonomic tone and reduce somatic stress:

• Thoracolumbar and sacral adjustments can influence sympathetic-parasympathetic balance, aiding HPA axis regulation.
• Soft tissue work around the pelvic girdle improves blood flow and lymphatic drainage, potentially easing dysmenorrhea.
• Prescribed movement strategies (hip hinge patterns, gluteal activation) improve insulin sensitivity and pelvic stability.

These techniques complement medical therapy by reducing neurogenic stress and enabling lifestyle adherence.

Medication pearls and safety

• Metformin: Start 500 mg nightly, titrate toward 2,000–2,100 mg/day as tolerated; GI effects often diminish with uptake of the gut’s serotonin/GLP modulation.
• GLP-1 agents (semaglutide, exenatide): effective for insulin resistance phenotypes; titrate to avoid GI effects and support satiety/sustainable weight changes (Davies et al., 2015).
• Spironolactone: avoid in pregnancy, monitor potassium and blood pressure; blocks androgen receptors without addressing gut/insulin etiologies—use as adjunct.
• Hormone therapy: in women with low SHBG and insulin resistance, start low and slow with testosterone due to heightened sensitivity and side-effect risk.

Fertility and long horizons

Restoring cycles and ovulation can take 1–2 years with comprehensive care. I have seen patients conceive naturally after sustained gut repair, insulin reduction, sleep optimization, and balanced thyroid/adrenal support—sometimes unexpectedly—once the axis normalizes. The physiology tracks: improved insulin status raises SHBG, reduces free androgen excess, normalizes LH pulsatility, and supports folliculogenesis.

Section 3: PSA, Percent Free PSA, Velocity, and Smarter Referrals

For men considering testosterone therapy or presenting with urogenital symptoms, PSA interpretation must be nuanced. Total PSA alone is specific but not very sensitive; adding percent free PSA and PSA velocity improves risk stratification (Catalona et al., 1998; Loeb et al., 2012).

• Percent free PSA: Lower percentages indicate a higher risk of prostate cancer. <10% often suggests a>50% likelihood; 10–20% is intermediate; >20% is low risk (Catalona et al., 1998).
• PSA velocity: Rapid increase (e.g., >0.75–2.0 ng/mL/year depending on baseline) may indicate aggressive pathology (Loeb et al., 2012).
• Finasteride lowers total PSA by ~50% but does not alter the percent free PSA—interpretation requires adjustment.

Clinical flow I use

• If total PSA >4 ng/mL, I order percent free PSA automatically to avoid repeat phlebotomy.
• If percent free PSA <10%: high suspicion—refer for imaging and urology consult.
• If 10–20%: treat potential prostatitis if symptomatic and retest after ~3 months.
• If >20%: low likelihood—monitor and retest.
• Prefer 3T multiparametric prostate MRI to localize lesions and differentiate prostatitis from neoplasm before invasive biopsy when feasible (Barentsz et al., 2012).

Why this matters before testosterone therapy

Before starting testosterone in men, confirm PSA ❤️ ng/mL and absence of overt BPH or suspicious trends, aligning with prudent clinical practice. Urologists differ; some request a repeat PSA in 6 months. I collaborate closely, leveraging imaging to prevent unnecessary biopsies and to identify chronic prostatitis, a common cause of PSA bumps. We also educate patients that intercourse and mechanical stimulation can transiently elevate total PSA but not percent free PSA.

Integrative chiropractic care fits

• Lumbo-pelvic adjustments and pelvic floor neuromuscular re-education can reduce pelvic congestion and pain in chronic prostatitis, complementing antibiotics/anti-inflammatories when indicated.
• Stress management, diaphragmatic breathing, and ribcage mobility work support autonomic balance, potentially reducing prostatic inflammation via neuroimmune modulation.

Section 4: DHEA: Neurosteroid Power, Mood, Libido, and Cognition

DHEA and DHEA-S decline after the 20s and affect mood, libido, cognition, vascular health, and skin integrity. DHEA functions as a neurosteroid, synthesized within the CNS, and interacts with GABAergic/glutamatergic systems, modulating resilience and sexual function (Maninger et al., 2009; Wolf & Kirschbaum, 2015).

Clinical observations

I often see women with “healthy” total and free testosterone who still report low libido, anhedonia, and poor orgasm quality. Their DHEA-S is often in the double digits rather than the robust triple digits. Adding compounded DHEA in low doses (5–10 mg for women; ~20 mg for men) can improve sexual function and mood, likely via CNS receptor effects and peripheral conversion pathways, including DHT modulation in females. We avoid DHEA in PCOS when DHEA-S is already elevated, as more DHEA can aggravate hyperandrogenic symptoms.

Physiology and dosing rationale

• DHEA supports membrane fluidity, mitochondrial signaling, and neurovascular health.
• Aim for optimal range rather than population averages; retest 6–8 weeks after initiation.
• Prefer compounded pharmaceutical-grade DHEA due to supplement variability; if OTC is used, start around 25 mg cautiously and monitor.

Safety pearls

• Monitor lipid profile, mood, acne/hair changes, and, in men, potential prostate symptoms.
• Align DHEA use with the broader endocrine plan—thyroid optimization alone can raise DHEA in some patients, so sequence matters.

Integrative chiropractic care fits

• Vagus-focused care—upper cervical and thoracic mobilization, breath mechanics, and stress-lowering routines—synergizes with DHEA’s neurosteroid role by improving autonomic tone, sleep quality, and adherence to exercise protocols, thereby further enhancing neuroendocrine balance.

Section 5: Lifestyle, Gut, and Clinical Protocols That Change Trajectories

Lifestyle changes are not adjuncts; they are central modulators of endocrine physiology.

• Nutrition: Anti-inflammatory, fiber-rich diets reduce endotoxemia, improve insulin signaling, and modulate SHBG. Low-glycemic, phytonutrient-dense patterns support gut microbial diversity (Borgo et al., 2023).
• Fasting windows: Intermittent fasting can lower insulin and improve leptin/ghrelin dynamics, supporting menstrual regularity in some PCOS phenotypes.
• Movement: Strength training improves insulin sensitivity; hip-dominant compound lifts are especially effective in PCOS and metabolic syndrome.
• Sleep and stress: Normalizing the HPA axis reduces cortisol-driven insulin resistance; chiropractic care supports mechanoreceptor input to autonomic regulation.
• Targeted supplements: Where appropriate and evidence-based, consider magnesium, omega-3s, and in select cases botanicals that modulate GLP-1 and gut ecology; dose responsibly and monitor.

Clinical reasoning in protocol design

• Start by stabilizing the gut and insulin resistance; this raises SHBG and lowers free androgen burden.
• Add receptor blockers for symptom relief while root causes are addressed.
• Sequence hormones cautiously in insulin-resistant women—begin low, reassess frequently.
• In men, scrutinize PSA patterns before testosterone; use percent free PSA and MRI to avoid unnecessary biopsies.
• Evaluate DHEA in persistent mood/libido complaints even when testosterone appears adequate.

Conclusion: Integrated Care, Better Outcomes

Endocrine care succeeds when it integrates physiology, evidence, and patient realities. By understanding SHBG as a metabolic barometer, reframing PCOS through gut-insulin mechanisms, optimizing PSA decision-making with percent free and velocity, and leveraging DHEA as a neurosteroid, we make better, safer choices. Integrative chiropractic care fits naturally here—aligning the structure, calming the autonomic nervous system, and enabling lifestyle practices that enhance insulin sensitivity and neuroendocrine resilience. This is how we help patients move from symptoms to sustainable health.

---

References

• Catalona, W. J., Partin, A. W., Slawin, K. M., et al. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA.
• Barentsz, J. O., Richenberg, J., Clements, R., et al. (2012). ESUR prostate MR guidelines 2012. European Radiology.
• Davies, M. J., Bergenstal, R., Bode, B., et al. (2015). Efficacy of liraglutide in adults with type 2 diabetes: LEAD trials. Diabetes Care.
• Ding, E. L., Song, Y., Manson, J. E., & Rexrode, K. M. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. The New England Journal of Medicine.
• Loeb, S., Carter, H. B., Kettermann, A., et al. (2012). Prostate-specific antigen velocity in men with prostate cancer treated surgically. BJU International.
• Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S). Frontiers in Neuroendocrinology.
• Plymate, S. R., et al. (2022). SHBG, metabolic syndrome, and cardiovascular risk: mechanistic and clinical insights. Endocrine Reviews.
• Teede, H. J., Misso, M. L., Costello, M. F., et al. (2018). International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction.
• UKPDS Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. The Lancet.